DMAAU
Drugs Made In America Acquisition Corp. UnitsKey Statistics
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. Units (DMAAU) is a special purpose acquisition company (SPAC) focused on merging with innovative firms within the pharmaceutical and healthcare sectors. Leveraging a seasoned management team with deep industry experience, DMAAU aims to address the increasing demand for domestic drug production amid rising concerns over healthcare affordability and accessibility in the U.S. This strategic approach positions DMAAU as an attractive opportunity for institutional investors looking to engage with transformative healthcare solutions that can shape the future of the industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.22 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 18.80% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $29.17M |
| Float | $27.90M |
| % Insiders | 17.88% |
| % Institutions | 1.54% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DMAAU and any ticker you trade — then tracks every position and per-strategy win rate.